Sarissa Capital Management LP Q3 2023 significant ownership

Add to watchlist

Sarissa Capital Management LP is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

Sarissa Capital Management LP Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Alkermes plc.August 24, 20238,323,4005.0%
Innoviva, Inc.May 15, 20236,904,00010.5%
IRONWOOD PHARMACEUTICALS INCMarch 01, 202114,890,0009.3%
Iterum Therapeutics plcSold outFebruary 12, 202100.0%
BIOCRYST PHARMACEUTICALS INCJanuary 25, 20218,844,0005.0%
Mersana Therapeutics, Inc.January 25, 20213,770,0005.5%
MEDICINES CO /DESold outJanuary 07, 202000.0%
Regulus Therapeutics Inc.January 03, 20207,935,32229.4%
NOVELION THERAPEUTICS INC.November 09, 2018909,2964.6%
APRICUS BIOSCIENCES, INC.September 05, 20181,152,4554.8%
EMMAUS LIFE SCIENCES, INC.April 03, 2018497,6571.4%
NOVELION THERAPEUTICS INC.August 04, 2017? ?
ARIAD PHARMACEUTICALS INCSold outFebruary 21, 201700.0%
Aegerion Pharmaceuticals, Inc.Sold outNovember 30, 201600.0%
VIVUS INCJuly 23, 2013? ?

Compare quarters

Export Sarissa Capital Management LP's holdings

CSVXLS